Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

Journal of Clinical Oncology

Volumn 13, Issue 1, 1995, Pages 70-78

  Van Der Zee, Ate G J ^b   Hollema, Harry ^b   Suurmeijer, Albert J H ^b   Krans, Mindert ^b   Sluiter, Wim J ^b   Willemse, Pax H B ^b   Aalders, Jan G ^b   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; SURVIVAL TIME; TISSUE DISTRIBUTION;

EID: 0028830165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1995.13.1.70     Document Type: Article

References (45)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
2. Van Houwelingen JC, Bokkel Huinink W, Van Der Burg AT, et al: Predictability of the survival of patients with ovarian cancer. J Clin Oncol 7:769-773, 1989
3. Perez RP, Hamilton TC, Ozols RF, et al: Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71:1571-1580, 1993
4. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
5. Tsai C-M, Chang K-T, Perng R-P, et al: Correlation of intrinsic chemoresistance of non-small-cell cancer cell lines with HER-2/ neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85:897-901, 1993
6. Moscow JA, Cowan KH: Multidrug resistance. J Natl Cancer Inst 80:14-20, 1988
7. Eck L, Pavich D, Fruehauf JP: MDR-1 expression by human ovarian tumors is associated with Taxol resistance. Proc Am Assoc Cancer Res 34:1388, 1993 (abstr)
8. Meijer C, Mulder NH, de Vries EGE: The role of detoxifying systems in resistance of tumor cells to cisplatin and Adriamycin. Cancer Treat Rev 17:389-398, 1990
9. Van der Zee AGJ, van Ommen B, Meijer C, et al: Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer 66:229-234, 1992
10. Bargman CI, Hung MC, Weinberg RA: The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:226-230, 1986
11. Yu D, Wolf JK, Scanlon M, Price JE, et al: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53:891-898, 1993
12. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
13. Vogelstein B, Kinzler KW: P53 function and dysfunction. Cell 70:523-526, 1992
14. Harris CC, Holstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993
15. International Federation of Gynecology and Obstetrics: Changes in definitions of clinical staging for cancer of the cervix and ovary. Am J Obstet Gynecol 156:236-241, 1987
16. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. The Hague, the Netherlands, Switzerland, Nijhoff, 1979
17. Serov SF, Scully RE, Sobin LH: Histological typing of ovarian tumors. Geneva, Switzerland, World Health Organization 1973, pp 17-18
18. Sobre B, Frankendal B, Veress B: Importance of histological grade in the prognosis of epithelial ovarian carcinomas. Obstet Gynecol 59:567-573, 1982
19. van den Berg FM, Baas IO, Polak MM, et al: Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol 142:381-385, 1993
20. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II, Analysis and examples. Br J Cancer 35:1-39, 1977
21. Finstad CL, Yin BWT, Gordon CM, et al: Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: A problem of quality control for immunohistochemical analysis. J Histochem Cytochem 39:1603-1610, 1991
22. Bourhis H, Goldstein LJ, Riou G, et al: Expression of a human multidrug gene in ovarian carcinomas. Cancer Res 49:5062-5065, 1989
23. Van der Zee AGJ, Hollema H, de Jong S, et al: P-glycoprotein and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51:5915-5920, 1991
24. Holzmayer TA, Hilsenbeck S, Von Hoff DD, et al: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84:1486-1491, 1992
25. Ramael M, Van den Bossche J, Buysse C, et al: Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. J Pathol 167:5-8, 1992
26. Weinstein RS, Kuszak JR, Kluskens LF, et al: P-glycoproteins in pathology: The multidrug resistance gene family in humans. Hum Pathol 21:34-48, 1990
27. Broxterman HJ, Pinedo HM, Kuiper CM, et al: Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int J Cancer 43:340-343, 1989
28. Omura GA, Buyse M, Marconi S, et al: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. Ovarian cancer meta-analysis project. J Clin Oncol 9:1668-1674, 1991
29. Van der Zee AGJ, de Jong S, Keith N, et al: Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 54:279-286, 1994
30. Crombach G: CA 125 in prognosis of ovarian cancer. Anticancer Res 13:1651-1654, 1993
31. Murphy D, McGown AT, Hall A, et al: Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer 66:937-942, 1992
32. Green JA, Robertson LJ, Clark AH: Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer 68:235-239, 1993
33. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
34. Winstanley J, Cooke T, Murray GD, et al: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63:447-450, 1991
35. Scambia G, Benedetti Panici P, Ferrandina G, et al: Expression of HER-2/neu oncoprotein. DNA-ploidy and S-phase fraction in advanced ovarian cancer. Int J Gynecol Cancer 3:271-278, 1993
36. Rubin SC, Finstad CL, Wong GY, et al: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 168:162-169, 1993
37. Hancock MC, Langton BC, Chan PT, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
38. Marks JR, Davidoff AM, Kerns BJ, et al: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-2984, 1991
39. Kohler MF, Kerns BJ, Humphrey PA, et al: Mutation and overexpression of p53 in early stage epithelial ovarian cancer. Obstet Gynecol 81:643-650, 1993
40. Kerns BJM, Jordan PA, Moore MBH, et al: p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 40:1047-1051, 1992
41. Bosari S, Viale G, Radelli U, et al: p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 24:1175-1179, 1993
42. Hartman LC, Podratz KC, Keeney GL, et al: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-69, 1994
43. Vile RG: p53: A gene for all tumours? Br Med J 307:1226-1227, 1993
44. Chin K-V, UedaK, Pastan I, et al: Modulation of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462, 1992
45. Dabholkar M, Bostick-Bruton F, Weber C, et al: ERCC1 and ERCC2 in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517, 1992